REGENXBIO Statistics

Total Valuation

REGENXBIO has a market cap or net worth of $541.79 million. The enterprise value is $639.70 million.

Market Cap	541.79M
Enterprise Value	639.70M

Important Dates

The next estimated earnings date is Thursday, August 6, 2026, before market open.

Earnings Date	Aug 6, 2026
Ex-Dividend Date	n/a

Share Statistics

REGENXBIO has 51.70 million shares outstanding. The number of shares has increased by 1.81% in one year.

Current Share Class	51.70M
Shares Outstanding	51.70M
Shares Change (YoY)	+1.81%
Shares Change (QoQ)	+1.31%
Owned by Insiders (%)	8.31%
Owned by Institutions (%)	72.10%
Float	43.03M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	6.17
Forward PS	2.28
PB Ratio	25.66
P/TBV Ratio	25.70
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	7.28
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 2.62, with a Debt / Equity ratio of 11.78.

Current Ratio	2.62
Quick Ratio	2.44
Debt / Equity	11.78
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	-5.69

Financial Efficiency

Return on equity (ROE) is -196.43% and return on invested capital (ROIC) is -203.58%.

Return on Equity (ROE)	-196.43%
Return on Assets (ROA)	-38.53%
Return on Invested Capital (ROIC)	-203.58%
Return on Capital Employed (ROCE)	-94.79%
Weighted Average Cost of Capital (WACC)	11.30%
Revenue Per Employee	$236,717
Profits Per Employee	-$781,704
Employee Count	371
Asset Turnover	0.21
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +22.72% in the last 52 weeks. The beta is 1.03, so REGENXBIO's price volatility has been similar to the market average.

Beta (5Y)	1.03
52-Week Price Change	+22.72%
50-Day Moving Average	8.04
200-Day Moving Average	10.35
Relative Strength Index (RSI)	73.51
Average Volume (20 Days)	2,262,998

Short Selling Information

The latest short interest is 8.28 million, so 16.02% of the outstanding shares have been sold short.

Short Interest	8.28M
Short Previous Month	7.14M
Short % of Shares Out	16.02%
Short % of Float	19.24%
Short Ratio (days to cover)	4.24

Income Statement

In the last 12 months, REGENXBIO had revenue of $87.82 million and -$290.01 million in losses. Loss per share was -$5.60.

Revenue	87.82M
Gross Profit	-172.67M
Operating Income	-256.69M
Pretax Income	-290.01M
Net Income	-290.01M
EBITDA	-241.17M
EBIT	-256.69M
Loss Per Share	-$5.60

Full Income Statement

Balance Sheet

The company has $150.49 million in cash and $248.40 million in debt, giving a net cash position of -$97.91 million or -$1.89 per share.

Cash & Cash Equivalents	150.49M
Total Debt	248.40M
Net Cash	-97.91M
Net Cash Per Share	-$1.89
Equity (Book Value)	21.08M
Book Value Per Share	0.41
Working Capital	115.41M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -$233.78 million and capital expenditures -$2.63 million, giving a free cash flow of -$236.40 million.

Operating Cash Flow	-233.78M
Capital Expenditures	-2.63M
Depreciation & Amortization	15.52M
Net Borrowing	n/a
Free Cash Flow	-236.40M
FCF Per Share	-$4.57

Full Cash Flow Statement

Margins

Gross Margin	-196.61%
Operating Margin	-292.28%
Pretax Margin	-330.23%
Profit Margin	n/a
EBITDA Margin	-274.61%
EBIT Margin	-292.28%
FCF Margin	n/a

Dividends & Yields

REGENXBIO does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-1.81%
Shareholder Yield	-1.81%
Earnings Yield	-53.53%
FCF Yield	-43.63%

Analyst Forecast

The average price target for REGENXBIO is $24.36, which is 132.44% higher than the current price. The consensus rating is "Buy".

Price Target	$24.36
Price Target Difference	132.44%
Analyst Consensus	Buy
Analyst Count	11
Revenue Growth Forecast (3Y)	31.23%
EPS Growth Forecast (3Y)	n/a

Stock Forecasts

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

REGENXBIO has an Altman Z-Score of -5.84 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-5.84
Piotroski F-Score	1